Jedd D. Wolchok

Identifying Targets to Mitigate Immunotherapy-Associated Immune-Related Adverse Events

National Cancer Institute · R01

PI · $703.4K · Weill Medical Coll of Cornell Univ

Determining the Role of Neutrophils in Anti-Tumor Immunity and Immune-Related Adverse Events in the Context of T Cell-Based Therapies

National Cancer Institute · R01

PI · $1.4M · Weill Medical Coll of Cornell Univ

Investigational Cancer Therapeutics Training Program (ICTTP)

National Cancer Institute · T32

PI · $4.2M · Sloan-Kettering Inst Can Research

MSK Immuno-Oncology for the Translational Researcher Short Course

National Cancer Institute · UE5

PI · $983.4K · Sloan-Kettering Inst Can Research

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Principal investigator · Completed · Phase 1, Phase 2

Memorial Sloan Kettering Cancer Center

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

Principal investigator · Withdrawn · Phase 1, Phase 2

Ludwig Institute for Cancer Research

Study of ADI-PEG 20 in Patients With Advanced Melanoma

Principal investigator · Completed · Phase 1, Phase 2

Ludwig Institute for Cancer Research

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

Principal investigator · Completed · Phase 1

Ichor Medical Systems Incorporated